Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.49 |
| ▸ | PPARD | Q03181 | 16/20 | 0.49 |
| ▸ | PPARA | Q07869 | 16/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013334 | 0.75 | PPARA (0.54) | PPARGPPARDPPARA | |
| SCHEMBL4015234 | 0.75 | PPARG (0.49) | PPARGPPARDPPARA | |
| SCHEMBL14010211 | 0.73 | PPARA (0.52) | PPARGPPARDPPARA | |
| SCHEMBL14830565 | 0.72 | CYP17A1 (0.50) | CYP17A1CYP1A2PTGS1PTGS2 | |
| SCHEMBL6100785 | 0.72 | GRM2 (0.40) | PPARGPPARACYP1A2 | |
| SCHEMBL13863170 | 0.71 | MAPT (0.46) | PPARGPPARDPPARA | |
| SCHEMBL7041390 | 0.69 | PPARA (0.67) | PPARGPPARDPPARA | |
| SCHEMBL4019361 | 0.69 | PPARA (0.47) | PPARGPPARDPPARA | |
| SCHEMBL12844155 | 0.68 | PTGS1 (0.56) | PTGS1PTGS2 | |
| SCHEMBL10658435 | 0.66 | PPARG (0.53) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-10429384-B2 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190022077-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION | 2019-01-24 | — | — | US | disclosed |
| EP-3398599-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | Omeros Corporation (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2018-09-04 | — | — | US | disclosed |
| CN-106692144-A | Compositions and methods for prophylaxis and treatment of addictions | 奥默罗斯公司 | 2017-05-24 | — | — | CN | disclosed |
| US-20170027920-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OMEROS CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-20160331729-A9 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OMEROS CORPORATION (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2866817-A2 | ANDROGRAPHIS PANICULATA COMPOSITIONS AND METHODS FOR TREATMENT OF ADDICTIONS | Omeros Corporation (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140072662-A1 | Andrographis Paniculata Compositions and Methods for Treatment of Addictions | OMEROS CORPORATION | 2014-03-13 | — | — | US | disclosed |
| US-7232828-B2 | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1536785-B1 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS INC (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070054949-A1 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | BETHESDA PHARMACEUTICALS, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007022518-A2 | NEW USES OF GLUCOREGULATORY PROTEINS | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1536785-A4 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1536785-A2 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | Bethesda Pharmaceuticals, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050020654-A1 | Novel PPAR agonists, pharmaceutical compositions and uses thereof | BETHESDA PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004082621-A2 | NOVEL PPAR AGONISTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BETHESDA PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040127443-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | BETHESDA PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2004014308-A2 | NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE | BETHESDA PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020654-A1 | Novel PPAR agonists, pharmaceutical compositions and uses thereof | PPARG, PPARD, PPARA | PPARG 1/4885PPARD 2/4885PPARA 3/4885 |
| US-20160331729-A9 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-10064850-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, OPRD1 | PPARG 7/4885PPARD 10/4885PPARA 4/4885 |
| US-20170027920-A1 | Compositions and Methods for Prophylaxis and Treatment of Addictions | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-20040127443-A1 | Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure | PPARA, PPARG, PPARD | PPARG 2/4885PPARD 3/4885PPARA 1/4885 |
| US-20070054949-A1 | Compositions comprising novel PPAR ligands and anti-hyperlipemic agents | HDLBP, PPARA, PPARG | PPARG 3/4885PPARD 6/4885PPARA 2/4885 |
| US-20190022077-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, PPARA | PPARG 7/4885PPARD 10/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.